SLC44A2 mediates the VSMC phenotypic switch in aortic aneurysm
(A) The switch from a contractile to a synthetic state is crucial for the development and progression of aortic aneurysm. SLC44A2 functions as a scaffolding protein that regulates the TGF-β/SMAD signaling pathway by forming a complex with NRP1 and ITGB3. This complex facilitates the release of activated TGF-β from latent TGF-β (latency-associated peptide [LAP]), which then binds to TGF-β receptors (TGFBRs) on the cell membrane, initiating the downstream phosphorylation of SMAD2/3. p-SMAD2/3 then translocates into the nucleus, where it regulates the expression of contractile markers ACTA2 and TAGLN, or synthetic markers KLF4 and OPN, associated with the VSMC phenotypic switch. SLC44A2 deficiency induced by siSLC44A2 disrupts the association between NRP1 and ITGB3, reduces the levels of TGF-β and p-SMAD2, and promotes the expression of synthetic VSMC markers KLF4 and OPN, while suppressing contractile VSMC markers ACTA2 and TAGLN, further contributing to the pathogenesis of aortic aneurysm. (B) RUNX1 acts as a key regulator of SLC44A2 by binding to the SLC44A2 promoter region and transcriptionally activating SLC44A2 gene expression. Lenalidomide (LEN), an activator of RUNX1, enhances SLC44A2 expression, boosting the SLC44A2/NRP1/ITGB3/TGF-β/SMAD signaling pathway. This promotes the expression of VSMC contractile markers ACTA2 and TAGLN, and represses synthetic VSMC markers KLF4 and OPN, inhibiting the phenotypic switching of VSMCs from a contractile to a synthetic state, ultimately suppressing the development of aortic aneurysm
Publication
SLC44A2-mediated phenotypic switch of vascular smooth muscle cells contributes to aortic aneurysm (2024) Mengen Xing, et al. J Clin Invest. 2024 Aug 15;134(16). Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | LAP | LAP | ncbigene_symbol | LAP | 7939 |
| Homo sapiens | Primates | LAP | LAP | ncbigene_synonym | ACP2 | 53 |
| Homo sapiens | Primates | LAP | LAP | ncbigene_synonym | TGFB1 | 7040 |
| Homo sapiens | Primates | LAP | LAP | ncbigene_synonym | PICALM | 8301 |
| Homo sapiens | Primates | LAP | LAP | ncbigene_synonym | LAP3 | 51056 |
| Homo sapiens | Primates | LAP | LAP | ncbigene_synonym | CENPJ | 55835 |
| Homo sapiens | Primates | LAP | LAP | ncbigene_synonym | PDON2 | 406237 |
| Homo sapiens | Primates | ITGB3 | ITGB3 | ncbigene_symbol | ITGB3 | 3690 |
| Homo sapiens | Primates | NRP1 | NRP1 | ncbigene_symbol | NRP1 | 8829 |
| Homo sapiens | Primates | NRP1 | NRP1 | ncbigene_synonym | NELL1 | 4745 |
| Homo sapiens | Primates | SLC44A2 | SLC44A2 | ncbigene_symbol | SLC44A2 | 57153 |
| Homo sapiens | Primates | TGF-B | TGFB | famplex_relations | TGFB2 | 7042 |
| Homo sapiens | Primates | TGF-B | TGFB | famplex_relations | TGFB3 | 7043 |
| Homo sapiens | Primates | TGFBR | TGFBR | famplex_relations | TGFBR1 | 7046 |
| Homo sapiens | Primates | TGFBR | TGFBR | famplex_relations | TGFBR2 | 7048 |
| Homo sapiens | Primates | TGFBR | TGFBR | famplex_relations | TGFBR3 | 7049 |
| Homo sapiens | Primates | p-SMAD2/3 | SMAD3 | ncbigene_symbol | SMAD3 | 4088 |
| Homo sapiens | Primates | p-SMAD2/3 | SMAD2 | ncbigene_symbol | SMAD2 | 4087 |
| Homo sapiens | Primates | ↓ACTA2 | ACTA2 | ncbigene_symbol | ACTA2 | 59 |
| Homo sapiens | Primates | TAGLN | TAGLN | ncbigene_symbol | TAGLN | 6876 |
| Homo sapiens | Primates | KLF4 | KLF4 | ncbigene_symbol | KLF4 | 9314 |
| Homo sapiens | Primates | OPN | OPN | ncbigene_synonym | SPP1 | 6696 |
| Homo sapiens | Primates | RUNX1 | RUNX1 | ncbigene_symbol | RUNX1 | 861 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Nucleus | nucleus | nucleus | chebi:33252 | |
| Lenalidomide | lenalidomide | 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione | chebi:63791 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|